5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine | 179120-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine
• 英文别名: altinicline；SIB-1765F；3-ethynyl-5-(1-methylpyrrolidin-2-yl)-pyridine；3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine；3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
• CAS: 179120-51-5
• 化学式: C₁₂H₁₄N₂
• 分子量: 186.257
• InChiKey: NUPUDYKEEJNZRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine 以80%的产率得到5-(1-Methyl-2-pyrrolidinyl)-3-pyridinylpropiolic acid
  参考文献：
  名称：

  Nicotine immunogen

  摘要：

  一种具有以下结构式(a)的5-或6-烟碱基-连接蛋白质化合物和免疫原，其中X为—NH—CO—或NH—或—C≡C—或—C═C—或CH2—；Y为—(CH2)k—或—(CH2)m—C6H10—(CH2)n—或(CH2)m—C6H4—(CH2)n—，当Z为—NH—时，但X不为—NH—CO—时，Y为(CH2)5且Z为—NH—；当Z为—CO—时，X为—NH—CO—或—C≡C—或—C═C—或CH2—，Y为—(CH2)m—C6H10—(CH2)n—或—(CH2)m—C6H4—(CH2)n—；当Z为—CO—时，X为—C≡C—或—C═C—，Z为—CO—，Y为(CH2)k—。该化合物可用作药物，适宜以药物组合物的形式使用。此外，还描述了一种用于预防性和/或治疗性免疫治疗尼古丁依赖性的方法，以实现烟草制品对健康的减害作用。

  公开号：

  US06656469B1
• 作为产物：
  描述：

  5-(2-hydroxy-2-methylbut-3-ynyl)-3-(1-methyl-2-pyrrolidinyl)pyridine 在 sodium hydride 作用下， 以 甲苯 为溶剂， 以97%的产率得到5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine
  参考文献：
  名称：

  A Practical and Efficient Synthesis of the Selective Neuronal Acetylcholine-Gated Ion Channel Agonist (S)-(−)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y)

  摘要：

  An efficient, high-yielding synthetic procedure for the preparation of the novel neuronal acetylcholine-gated ion channel agonist (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate [(S)-2, SIB-1508Y] is described. The key steps in the process include the lithium bis(trimethylsilyl)amide-mediated acylation of N-vinylpyrrolidinone with ethyl 5-bromonicotinate, a high-yielding sodium borohydride reduction of imine 5, and a new heteroaryl-alkyne cross-coupling protocol for the introduction of the ethyne moiety in (S)-2. The preparation of enantiomerically pure (S)-2 was accomplished via a combination of enantioselective reduction of imine 5 and crystallization of enantiomerically enriched 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine (7) as the dibenzoyl-L-tartaric acid salt.

  DOI：

  10.1021/jo971572d

文献信息

• Synthesis of nicotine derivatives from nicotine
  申请人：Comins L. Daniel

  公开号：US20050113336A1

  公开（公告）日：2005-05-26

  Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.

  描述了合成尼古丁类似物和衍生物的方法。在某些实施例中，这些方法利用了烷基或芳基硅烷取代的尼古丁类似物中间体。还描述了用于合成尼古丁和尼古丁类似物的中间体。
• Methods for the preparation of modulators of acetylcholine receptors
  申请人：Sibia Neurosciences, Inc.

  公开号：US05677459A1

  公开（公告）日：1997-10-14

  In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors, and are useful for a variety of therapeutic applications, such as the treatment of Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis; substance abuse including withdrawal syndromes and substitution therapy; neuroendocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders of nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma; cardiovascular dysfunction including hypertension and cardia arrhythmias, comedication in surgical procedures, and the like.

  根据本发明提供了一类吡啶化合物，这些化合物是乙酰胆碱受体的调节剂。本发明的化合物可以从其结合位点上排挤乙酰胆碱受体配体。发明的化合物可能作为乙酰胆碱受体的激动剂、部分激动剂、拮抗剂或变构调节剂，并且可用于各种治疗应用，如治疗阿尔茨海默病和其他涉及记忆丧失和/或痴呆的疾病（包括艾滋病痴呆）；注意力和专注障碍（如注意力缺陷障碍）；运动功能外围运动障碍，如帕金森病、亨廷顿病、吉尔·德·拉·图雷特综合症和迟发性运动障碍；情绪和情感障碍，如抑郁、恐慌、焦虑和精神病；物质滥用，包括戒断综合症和替代疗法；神经内分泌紊乱和食物摄入失调，包括暴食症和厌食症；疼痛感知和疼痛控制障碍；自主神经障碍，包括胃肠道运动和功能障碍，如炎症性肠病、肠易激综合症、腹泻、便秘、胃酸分泌和溃疡；嗜铬细胞瘤；心血管功能障碍，包括高血压和心律失常，手术过程中的联合用药等。
• Modulators of acetylcholine receptors
  申请人：SIBIA Neurosciences, Inc.

  公开号：US05594011A1

  公开（公告）日：1997-01-14

  g In accordance with the present invention, there is provided a class of pyridine compounds which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors, and are useful for a variety of therapeutic applications, such as the treatment of Alzheimer's disease and other disorders involving memory loss and/or dementia; disorders of attention and focus; disorders of extrapyramidal motor function; mood and emotional disorders; substance abuse including withdrawal syndromes and substitution therapy; neuroendocrine disorders and dysregulation of food intake; disorders of nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function; pheochromocytoma; cardiovascular dysfunction hypertension and cardia arrhythmias; comedication in surgical procedures, and the like.

  根据本发明，提供了一类吡啶化合物，它们是乙酰胆碱受体的调节剂。本发明的化合物可将乙酰胆碱受体配体从其结合位点上置换出来。本发明的化合物可作为乙酰胆碱受体的激动剂、部分激动剂、拮抗剂或变构调节剂，并可用于多种治疗应用，例如治疗阿尔茨海默病和其他涉及记忆丧失和/或痴呆的疾病；注意力和专注障碍；外展性运动功能障碍；情绪和情感障碍；物质滥用，包括戒断综合症和替代疗法；神经内分泌障碍和食物摄入失调；痛觉和疼痛控制障碍；自主神经障碍，包括胃肠动力和功能障碍；嗜铬细胞瘤；心血管功能障碍，高血压和心律失常；手术程序中的联合用药等。
• Di- and heptavalent nicotinic analogues to interfere with α7 nicotinic acetylcholine receptors
  作者：Yoan Brissonnet、Romulo Araoz、Rui Sousa、Lucie Percevault、Sami Brument、David Deniaud、Denis Servent、Jean-Yves Le Questel、Jacques Lebreton、Sébastien G. Gouin

  DOI：10.1016/j.bmc.2019.01.013

  日期：2019.3

  In the field of nicotinic acetylcholine receptors (nAChRs), recognized as important therapeutic targets, much effort has been dedicated to the development of nicotinic analogues to agonize or antagonize distinct homo- and heteropentamers nAChR subtypes, selectively. In this work we developed di- and heptavalent nicotinic derivatives based on ethylene glycol (EG) and cyclodextrin cores, respectively

  在被认为是重要治疗靶标的烟碱乙酰胆碱受体（nAChRs）领域中，已致力于开发烟碱类似物以选择性地激动或拮抗不同的同戊和异戊二烯nAChR亚型。在这项工作中，我们分别基于乙二醇（EG）和环糊精核心开发了二价和七价烟碱衍生物。该化合物对非洲爪蟾卵母细胞表达的α7nAChR乙酰胆碱诱导的电流具有浓度依赖性抑制作用。用二价烟碱衍生物观察到有趣的特征，该二价烟碱衍生物以间隔臂长度的函数作为具有不同抑制浓度（IC50）的拮抗剂。最好的二价化合物与单价参比化合物相比，IC50降低了16倍（12 vs 195 µM）。
• [EN] PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS<br/>[FR] MODULATEURS A BASE DE PYRIDINE AGISSANT SUR LES RECEPTEURS DE L'ACETYLCHOLINE
  申请人：SIBIA NEUROSCIENCES, INC.

  公开号：WO1996015123A1

  公开（公告）日：1996-05-23

  (EN) In accordance with the present invention, there is provided a class of pyridine compounds of formula (I) which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors, and are useful for a variety of therapeutic applications, such as the treatment of Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis; substance abuse including withdrawal syndromes and substitution therapy; neuroendocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders of nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma; cardiovascular dysfunction including hypertension and cardia arrhythmias, comedication in surgical procedures, and the like.(FR) L'invention concerne une classe de composés de pyridine de formule (I) qui constituent des modulateurs des récepteurs de l'acétylcholine. Ces composés déplacent les ligands des récepteurs de l'acétylcholine de leurs sites de liaison. Ils peuvent agir comme agonistes, agonistes partiels, antagonistes ou modulateurs allostériques des récepteurs de l'acétylcholine et conviennent à diverses thérapies telles que les traitements de la maladie d'Alzheimer et d'autres troubles impliquant des pertes de mémoire et/ou la démence (y compris celle due au Sida); des troubles de l'attention et de la concentration (tels que le trouble déficitaire de l'attention); des troubles des fonctions motrices extrapyramidales tels que la maladie de Parkinson, la chorée de Huntington, la maladie de Gilles de la Tourette et les dyskinésies tardives; des troubles de l'humeur et des émotions tels que dépression, panique, anxiété et psychose; l'usage de drogues, y compris les syndromes de sevrage, et dans les thérapies de substitution; des troubles neuro-endocriniens et des dérèglements alimentaires, y compris la boulimie et l'anorexie; des troubles de la nociception et ceux dus à la lutte contre la douleur; des troubles du système nerveux autonome, y compris les dysfonctionnements de la motilité et des fonctions intestinaux, tels que maladie intestinale inflammatoire, syndrome du côlon irritable, diarrhée, constipation, troubles de la sécrétion d'acide gastrique et ulcères; du phéochromocytome; des dysfonctionnements cardiovasculaires, y compris l'hypertension et les arythmies cardiaques; des comédications relatives aux procédures chirurgicales, etc.

  根据本发明，提供了一类式为(I)的吡啶化合物，它们是乙酰胆碱受体调节剂。本发明的化合物将乙酰胆碱受体配体从其结合位点上排挤出来。发明的化合物可以作为乙酰胆碱受体的激动剂、部分激动剂、拮抗剂或异构调节剂，并且可用于各种治疗应用，例如治疗阿尔茨海默病和其他涉及记忆丧失和/或痴呆（包括艾滋病痴呆）的疾病；注意力和集中力障碍（如注意缺陷障碍）；运动功能失调疾病，如帕金森病、亨廷顿病、吉尔斯·德·拉·图雷特综合征和迟发性舞蹈症；情绪和情感障碍，如抑郁、恐慌、焦虑和精神病；物质滥用，包括戒断综合征和替代疗法；神经内分泌障碍和食欲调节失调，包括贪食症和厌食症；疼痛感知和控制障碍；自主神经障碍，包括胃肠动力和功能障碍，如炎症性肠病、肠易激综合征、腹泻、便秘、胃酸分泌和溃疡；嗜铬细胞瘤；心血管功能障碍，包括高血压和心律失常；手术过程中的联合用药等。